MedPath

Evaluation of Clinical Efficacy of Herbal Compound in the Treatment of NSLBP

Phase 4
Completed
Conditions
Low Back Pain
Interventions
Drug: herbal compound
Registration Number
NCT06336993
Lead Sponsor
Zhejiang Provincial Tongde Hospital
Brief Summary

The aim of this randomized controlled trial was to explore the clinical efficacy and safety of HXTL in the treatment of NSLBP based on TCM principles and to compare the clinical outcomes of different syndromes of NSLBP with celecoxib.In this study, 80 patients with NSLBP were recruited and randomly grouped to use TCM compound and celeoxib respectively for intervention. The pain status and lumbar function use scale of patients were scored before intervention, 1 week, 2 weeks and 3 weeks after intervention, and the adverse reactions of patients after medication were recorded, and the clinical efficacy of the two groups of patients was compared finally.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
71
Inclusion Criteria
  • a. Patients with low back pain who were seen between January 1, 2022 and June 16, 2023 were included;
  • b. meet the diagnostic criteria of NSLBP;
  • c. the age range was 20-90 years old;
  • d. agree to participate in the study and sign the informed consent;
Exclusion Criteria
  • a. those who are unable to communicate normally, such as those suffering from mental and cognitive diseases, and cannot cooperate with the treatment;
  • b. pregnant or lactating women;
  • c. patients who are allergic to the treatment components or sulfonamides;
  • d. patients with a history of coronary artery bypass grafting;
  • e. patients with active gastrointestinal ulcer or bleeding;
  • f. patients with severe heart failure;
  • g. Patients with hepatic and renal insufficiency.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
herbal compoundherbal compound-
celecoxibCelecoxib-
Primary Outcome Measures
NameTimeMethod
Visual Analogue Scalebaseline, 1 week, 2 week, 3 week after treating

The visual analogue scale (VAS) is used to assess pain. It is widely used in clinical practice worldwild. The basic method is to use a walking scale about 10cm long, marked with 10 scales on one side, and the two ends are respectively "0" and "10". 0 indicates no pain, and 10 indicates the most unbearable pain. A higher score means more intense pain.

Oswestry disability indexbaseline, 1 week, 2 week, 3 week after treating

The Oswestry Disability Index (ODI) consists of 10 questions about pain intensity, self-care, lifting, walking, sitting, standing, disturbance of sleep, sexual life, social life, and travel, with six options for each question. The maximum score for each question is 5. Select the first option to score 0 points, select the last option to score 5 points, if there are 10 questions have been answered, the scoring method is: actual score /50 (highest possible score) × 100%, if there is a question not answered, the scoring method is: Actual score /45 (highest possible score) x 100%, if higher indicates more severe dysfunction.

Japanese Orthopaedic Association Scoresbaseline, 1 week, 2 week, 3 week after treating

Japanese Orthopaedic Association Scores are evaluated from four aspects: conscious symptoms, objective examination, limit of daily activities and bladder function. Each part is composed of several questions, with 3-4 options for each question. The highest score for each question is 2 or 3 points. The overall score ranges from 0 to 29, with lower scores indicating greater dysfunction.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Tongde Hospital

🇨🇳

Hangzhou, Zhejiang, China

Tongde Hospital
🇨🇳Hangzhou, Zhejiang, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.